SXTP - Latest News
60 Degrees Pharmaceuticals, Inc. (SXTP), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $830,747. Beta to the broader market is 2.54.
The article list below shows the most recent SXTP headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent SXTP Headlines
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
globenewswire.com - Aug 14, 2026
WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
globenewswire.com - Jul 30, 2026
WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) (“60 Degrees” or the “Company”), a pharmaceutica
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
globenewswire.com - Jul 29, 2026
Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoqui
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
globenewswire.com - Jul 8, 2026
60 Degrees Pharma (Nasdaq: SXTP) secures exclusive option to develop castanospermine for tick-borne diseases, expanding its infectious disease pipelin
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
globenewswire.com - Jul 1, 2026
WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharm
How News Affects SXTP Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track SXTP's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked SXTP news questions
- What is the latest SXTP news headline?
- The most recent SXTP headline (Aug 14, 2026) is "60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the SXTP news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What SXTP news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual SXTP options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.